Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice

Viral Immunology

Volumn 26, Issue 4, 2013, Pages 268-276

  Noh, Youran ^a   Shim, Byoung Shik ^a   Cheon, In Su ^a   Rho, Semi ^a   Kim, Hee Joo ^a   Choi, Youngjoo ^a   Kang, Chang Yuil ^a   Chang, Jun ^b   Song, Man Ki ^a   Kim, Jae Ouk ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MATERNAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EOSINOPHIL; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LOEFFLER PNEUMONIA; MOUSE; NEWBORN; NEWBORN CARE; NONHUMAN; PROTECTION; REINFECTION; TH2 CELL; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; EOSINOPHILIA; FEMALE; GLYCOPROTEINS; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS;

EID: 84882401469     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0087     Document Type: Article

References (48)

1. Adkins B, Leclerc C, and Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nature Rev Immunol 2004; 4:553-564.
2. Blanco JC, Boukhvalova MS, Shirey KA, et al. New insights for development of a safe and protective RSV vaccine. Human Vaccines 2010;6:482-492.
3. Bouma A, De Jong MC, and Kimman TG. The influence of maternal immunity on the transmission of pseudorabies virus and on the effectiveness of vaccination. Vaccine 1997; 15:287-294.
4. Brandt C, Power UF, Plotnicky-Gilquin H, et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 1997; 176:884-891.
5. Cane PA, Matthews DA, and Pringle CR. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. J Gen Virol 1991;72:2091-2096.
6. Cane PA, Thomas HM, Simpson AF, et al. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol 1996;48:253-261.
7. Cormier SA, You D, and Honnegowda S. The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti-Infect Ther 2010;8:1371-1380.
8. Crowe JE Jr, Firestone CY, and Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001;167:3910-3918.
9. Culley FJ, Pollott J, and Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002;196:1381-1386.
10. De Bernardis F, Boccanera M, Adriani D, et al. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 2002;70:2725-2729.
11. Demirjian A, and Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol 2009;39:36-46.
12. Fields BN, Knipe DM, and Howley PM. Fields Virology. 3rd ed. Lippincott-Raven Publishers, Philadelphia. 1996
13. Garofalo R, Kimpen JL, Welliver RC, and Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992; 120:28-32.
14. Glezen WP, Paredes A, Allison JE, et al. 1981 Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-715.
15. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011;239:149-166.
16. Glezen WP, Taber LH, Frank AL, and Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-546.
17. Hacimustafaoglu M, Celebi S, Aynaci E, et al. The progression of maternal RSV antibodies in the offspring. Arch Dis Childhood 2004;89:52-53.
18. Hoare CM, DeBouck P, and Wiseman A. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies. Vaccine 1997;15:273-275.
19. Imaoka K, Miller CJ, Kubota M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998;161:5952-5958.
20. Johnson RP, and Povey RP. Vaccination against feline viral rhinotracheitis in kittens with maternally derived feline viral rhinotracheitis antibodies. J Am Vet Med Assoc 1985;186:149-152.
21. Johnson PR, Spriggs MK, Olmsted RA, and Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: Extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987;84:5625-5629.
22. Kim HW, Canchola JG, and Brandt CD, et al. 1969 Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-434.
23. Kim S, Joo DH, Lee JB, et al. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PloS One 2012;7:e32226.
24. Kovarik J, and Siegrist CA. Immunity in early life. Immunol Today 1998;19:150-152.
25. Mahon BP. The rational design of vaccine adjuvants for mucosal and neonatal immunization. Curr Med Chem 2001; 8:1057-1075.
26. Matsuse H, Behera AK, Kumar M, et al. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol 2000;164:6583-6592.
27. Murphy BR, Olmsted RA, Collins PL, et al. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1988;62:3907-3910.
28. Murphy BR, Prince GA, Collins PL, et al. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV). Vaccine 1991;9:185-189.
29. Nguyen TN, Power UF, Robert A, et al. The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents. PloS One 2012;7:e34331.
30. Perez-Yarza EG, Moreno A, Lazaro P, et al. The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature. Pediatr Infect Dis J 2007;26:733-739.
31. Piedra PA, Jewell AM, Cron SG, et al. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: Establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003;21: 3479-3482.
32. Plotnicky-Gilquin H, Goetsch L, Huss T, et al. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 1999;73:5637-5645.
33. Power UF. Respiratory syncytial virus (RSV) vaccines-Two steps back for one leap forward. J Clin Virol 2008;41 :38-44.
34. Power UF, Nguyen TN, Rietveld E, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001;184:1456-1460.
35. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997;230:155-166.
36. PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: Implications for responses to infection and vaccines. Nature Immunol 2011;12:189-194.
37. Rose S, Lichtenheld M, Foote MR, and Adkins B. Murine neonatal CD4 + cells are poised for rapid Th2 effector-like function. J Immunol 2007;178:2667-2678.
38. Rueda P, Delgado T, Portela A, et al. Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. J Virol 1991;65:3374-3378.
39. Saito M, Otake S, Ohmura M, et al. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant. J Infect Dis 2001;183:823-826.
40. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitisassociated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22.
41. Stensballe LG, Ravn H, Kristensen K, et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009;154:296-298.
42. Sullender WM, Mufson MA, Anderson LJ, and Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991;65:5425-5434.
43. Vannier P. Experimental infection of fattening pigs with pseudorabies (Aujeszky's disease) virus: Efficacy of attenuated live-and inactivated-virus vaccines in pigs with or without passive immunity. Am J Vet Res 1985;46:1498-1502.
44. Wagner DK, Graham BS, Wright PF, et al. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol 1986;24:304-306.
45. Waris ME, Tsou C, Erdman DD, et al. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996;70:2852-2860.
46. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 2003;22:S6-10; discussion S10-12.
47. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003;143:S112-117.
48. Xiang ZQ, and Ertl HC. Transfer of maternal antibodies results in inhibition of specific immune responses in the offspring. Virus Res 1992;24:297-314.